GeneDx slides on weak revenue despite 33% test volume growth
GeneDx Holdings fell short of revenue expectations and cut its full-year outlook, highlighting the tension between rapid volume growth and falling reimbursement rates in the rare disease diagnostics market.
GeneDx Holdings reported first-quarter results that missed revenue expectations, prompting management to lower full-year guidance and sending the stock down 25% over the past year. The genomics company closed at $60.65 on July 20, giving it a $1.80 billion market capitalization.
The shortfall was driven by softer average reimbursement rates and weakness in non-core business segments. For investors, the results underscore a persistent challenge in the diagnostics sector: translating rapid clinical adoption into consistent financial growth when insurance payouts fluctuate. Even so, the company's core operations showed underlying strength, with exome and genome test volumes surging 33% year over year.
Fred Alger Management highlighted the stock in its second-quarter 2026 investor letter for the Alger Small Cap Focus Fund. The fund managers noted that while the recent earnings miss weighed on investor sentiment, the business retains significant structural advantages.
The stock's struggles occurred during a broadly strong quarter for U.S. equities. The S&P 500 notched its best gain since 2020 by rising 15.2% in the second quarter, driven by a U.S.-Iran ceasefire and accelerated artificial intelligence investment. Against this macro backdrop, GeneDx's underperformance reflects company-specific headwinds rather than a broader healthcare selloff.
Despite the GeneDx drag, the Alger Small Cap Focus Fund's Class A shares outperformed the Russell 2000 Growth Index in the period. The fund benefited from strong showings in industrials and healthcare, even as financials and consumer discretionary positions lagged.
